QR Pharma Receives Seed Investment from Ben Franklin Technology Partners for Further Development of Clinical Stage Compounds to Treat Alzheimer’s Disease

QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease

TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma